In 2015, the World Health Organization (WHO) revised its 2004 classification of lung tumors to reflect the impact of genetic, clinical, and radiologic advances in the field.1 Among the revisions […] Read more
Treatment options for patients with malignant pleural mesothelioma (MPM) are limited. While patients with advanced or inoperable MPM are traditionally treated with cisplatin and pemetrexed as a standard first-line treatment, […] Read more
Although low-dose CT scans enable the detection of very small lung nodules in individuals who face a high risk of developing lung cancer, it is often impossible to quickly determine […] Read more
Despite the past decade’s accomplishments in identifying the genetic drivers of NSCLC, the complexity of these cancers continues to create barriers to effective targeted treatment. Finding strategies capable of overcoming […] Read more
Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%
October 15, 2021— Based on the results of phase III IMpower010, atezolizumab was approved by the U.S. Food and Drug Administration (FDA) as adjuvant treatment after surgery and chemotherapy for […] Read more
It is a trend many years in the making, but the time is ripe to fix the increasing problems with clinical trial consent documentation. The word count and complexity of […] Read more
Spine metastases represent a common complication of lung cancer and other cancers, with approximately 40% of patients developing clinically significant spinal metastatic disease and up to 90% developing subclinical micrometastases. […] Read more
Ophthalmologists are beginning to identify common adverse side effects seen in patients with cancer receiving immunotherapy. The IASLC Lung Cancer News spoke with Asim V. Farooq, MD, about how best to care for patients experiencing or susceptible to such toxicities. Dr. Farooq is associate professor of Ophthalmology and Vis... Read more
Ticiana Leal, MD, has moved to Emory University School of Medicine as associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology. […] Read more
In the National Lung Screening Trial, screening with 2 years of annual low-dose computed tomography (LDCT) achieved a 20% decrease in lung cancer mortality in high-risk populations when compared with […] Read more